Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2014 2013
Dec 15, 2022
AbCellera and AbbVie Partner to Advance New Antibody Therapies
Download PDFPDF format download (opens in new window)
Dec 01, 2022
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
Download PDFPDF format download (opens in new window)
Nov 10, 2022
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
Download PDFPDF format download (opens in new window)
Nov 08, 2022
AbCellera Reports Q3 2022 Business Results
Download PDFPDF format download (opens in new window)
Nov 04, 2022
AbCellera to Present at Upcoming Investor Conferences in November
Download PDFPDF format download (opens in new window)
Nov 02, 2022
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
Download PDFPDF format download (opens in new window)
Oct 11, 2022
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
Download PDFPDF format download (opens in new window)
Oct 05, 2022
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
Download PDFPDF format download (opens in new window)
Sep 21, 2022
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
Download PDFPDF format download (opens in new window)
Aug 09, 2022
AbCellera Reports Q2 2022 Business Results
Download PDFPDF format download (opens in new window)
Aug 03, 2022
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
Download PDFPDF format download (opens in new window)
Jul 27, 2022
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
Download PDFPDF format download (opens in new window)
Jul 12, 2022
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
Download PDFPDF format download (opens in new window)
Jun 29, 2022
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
Download PDFPDF format download (opens in new window)
May 10, 2022
AbCellera Reports Q1 2022 Business Results
Download PDFPDF format download (opens in new window)
May 03, 2022
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
Download PDFPDF format download (opens in new window)
Apr 26, 2022
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
Download PDFPDF format download (opens in new window)
Apr 12, 2022
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
Download PDFPDF format download (opens in new window)
Apr 08, 2022
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
Download PDFPDF format download (opens in new window)
Feb 24, 2022
AbCellera Reports Full Year 2021 Business Results
Download PDFPDF format download (opens in new window)
Feb 23, 2022
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
Download PDFPDF format download (opens in new window)
Feb 11, 2022
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
Download PDFPDF format download (opens in new window)
Feb 11, 2022
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Download PDFPDF format download (opens in new window)
Feb 10, 2022
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
Download PDFPDF format download (opens in new window)
Jan 27, 2022
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
Download PDFPDF format download (opens in new window)